Frey Noelle V, Svoboda Jakub, Andreadis Charalambos, Tsai Donald E, Schuster Stephen J, Elstrom Rebecca, Rubin Stephen C, Nasta Sunita D
Abramson Cancer Center of the Hospital of the University of Pennsylvania, 3400 Spruce, Philadelphia, PA 19104, USA.
Leuk Lymphoma. 2006 Sep;47(9):1894-901. doi: 10.1080/10428190600687653.
Primary lymphomas of the cervix and uterus are rare with approximately 150 cases reported in the world literature to date. Appropriate diagnosis is often delayed until the post-operative setting as clinical and radiographic presentations are non-specific. Several sub-types of lymphoma arising primarily in the cervix or uterus have been reported with diffuse large B-Cell lymphoma (DLBCL) being the most frequent. Due to the low incidence of this disease, no randomized clinical trials exist to help guide treatment. This study reports the experience of four patients with primary lymphomas of the uterus and cervix that reflect the heterogeneity of cases reported in the literature to date. The patients had a mean age at diagnosis of 46 (range 35 - 56) and presented with abnormal uterine bleeding. One patient was diagnosed by total abdominal hysterectomy (TAH), two patients were diagnosed by cervical biopsy and one patient was diagnosed by endometrial biopsy. Three patients had DLBCL and one patient had marginal zone lymphoma (MZL). All patients had stage IIE disease. Of the patients with DLBCL, one received chemotherapy followed by TAH and two received TAH followed by chemotherapy. Two of these three patients remain disease-free post-initial therapy with the third now disease-free post-salvage therapy and autologous stem cell transplant. The patient with MZL was treated with TAH alone and remains disease-free. Based on the case series and a review of available literature, primary lymphomas of the uterus or cervix are rare and require an individualized approach to treatment. In general, patients with limited stage disease should be treated with localized and systemic therapy to optimize chances of cure.
子宫颈和子宫原发性淋巴瘤较为罕见,迄今为止世界文献报道约150例。由于临床和影像学表现不具特异性,恰当诊断往往延迟至术后阶段。文献报道了几种主要发生在子宫颈或子宫的淋巴瘤亚型,其中弥漫性大B细胞淋巴瘤(DLBCL)最为常见。由于该疾病发病率低,尚无随机临床试验来指导治疗。本研究报告了4例子宫和子宫颈原发性淋巴瘤患者的经验,这些经验反映了迄今为止文献报道病例的异质性。患者诊断时的平均年龄为46岁(范围35 - 56岁),均表现为子宫异常出血。1例患者通过全腹子宫切除术(TAH)确诊,2例患者通过宫颈活检确诊,1例患者通过子宫内膜活检确诊。3例患者为DLBCL,1例患者为边缘区淋巴瘤(MZL)。所有患者均为IIE期疾病。在DLBCL患者中,1例先接受化疗,随后进行TAH,另外2例先进行TAH,随后接受化疗。这3例患者中有2例在初始治疗后无疾病复发,第3例在挽救治疗和自体干细胞移植后无疾病复发。MZL患者仅接受TAH治疗,目前无疾病复发。基于该病例系列及对现有文献的回顾,子宫或子宫颈原发性淋巴瘤罕见,需要个体化的治疗方法。一般来说,局限期疾病患者应接受局部和全身治疗,以优化治愈机会。